View Item 

Show simple item record

Incidence of Ischemic Colitis and Serious Complications of Constipation Among Patients Using Alosetron: Systematic Review of Clinical Trials and Post-Marketing Surveillance Data

dc.contributor.authorChang, Linen_US
dc.contributor.authorChey, William D.en_US
dc.contributor.authorHarris, Lucindaen_US
dc.contributor.authorOlden, Kevinen_US
dc.contributor.authorSurawicz, Christinaen_US
dc.contributor.authorSchoenfeld, Philip S.en_US
dc.date.accessioned2010-06-01T22:10:36Z
dc.date.available2010-06-01T22:10:36Z
dc.date.issued2006-05en_US
dc.identifier.citationChang, Lin; Chey, William D.; Harris, Lucinda; Olden, Kevin; Surawicz, Christina; Schoenfeld, Philip (2006). "Incidence of Ischemic Colitis and Serious Complications of Constipation Among Patients Using Alosetron: Systematic Review of Clinical Trials and Post-Marketing Surveillance Data." The American Journal of Gastroenterology 101(5): 1069-1079. <http://hdl.handle.net/2027.42/75196>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75196
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16606352&dopt=citationen_US
dc.format.extent252443 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights2006 by Am. Coll. of Gastroenterologyen_US
dc.titleIncidence of Ischemic Colitis and Serious Complications of Constipation Among Patients Using Alosetron: Systematic Review of Clinical Trials and Post-Marketing Surveillance Dataen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, Michiganen_US
dc.contributor.affiliationumVeterans Affairs Center for Excellence in Health Services Research, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherCenter for Neurovisceral Sciences & Women's Health, Departments of Medicine, UCLA and VA Greater Los Angeles Healthcare Center, Los Angeles, Californiaen_US
dc.contributor.affiliationotherDepartment of Gastroenterology, Mayo Clinic, Scottsdale, Arizonaen_US
dc.contributor.affiliationotherDivision of Gastroenterology, University of South Alabama School of Medicine, Mobile, Alabamaen_US
dc.contributor.affiliationotherDivision of Gastroenterology, University of Washington School of Medicine, Seattle, Washingtonen_US
dc.identifier.pmid16606352en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75196/1/j.1572-0241.2006.00459.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2006.00459.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceForster JM, Houghton LA, Whorwell PJ. Alosetron slows colonic transit in patients with irritable bowel syndrome. Gastroenterology 1996; 110: A630. [ abstract ]en_US
dc.identifier.citedreferenceDelvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849 – 55.en_US
dc.identifier.citedreferenceCamilleri M, Mayer E, Drossman D, et al. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149 – 51.en_US
dc.identifier.citedreferenceJones R, Holmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female non-constipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419 – 27.en_US
dc.identifier.citedreferenceCamilleri M, Northcutt AR, Kong S, et al. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: A randomized, placebo controlled study. Lancet 2000; 355: 1035 – 40.en_US
dc.identifier.citedreferenceLembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662 – 70.en_US
dc.identifier.citedreferenceBardhan K, Bodemar G, Geldor H, et al. A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 23 – 4.en_US
dc.identifier.citedreferenceLembo A, Olden K, Ameen V, et al. Effect of alosetron on bowel urgency and global symptoms in women with severe diarrhea-predominant IBS: Analysis of two controlled trials. Clin Gastroenterol Hepatol 2004; 2: 675 – 82.en_US
dc.identifier.citedreferenceChey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2195 – 203.en_US
dc.identifier.citedreferenceBearcroft CP, Andre EA, Farthing MJ. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: A segmental perfusion study. Aliment Pharmacol Ther 1997; 11 ( 6 ): 1109 – 14.en_US
dc.identifier.citedreferenceBerman SM, Chang L, Suyenobu B, et al. Condition specific deactivation of brain regions by 5HT3 receptor antagonist alosetron. Gastroenterology 2002; 123 ( 4 ): 969 – 77.en_US
dc.identifier.citedreference12.  American Gastroenterological Association Medical Position Statement: Guidelines on intestinal ischemia. Gastroenterology 2000; 118: 951 – 3.en_US
dc.identifier.citedreferenceBrandt LJ, Boley SJ. AGA technical review on intestinal ischemia. Gastroenterology 2000; 118: 954 – 68.en_US
dc.identifier.citedreference14.  Code of Federal Regulations, Title 21 Food and Drugs, Part 312, Section 312.32 IND Safety Reports.en_US
dc.identifier.citedreferenceViramontes BE, Camilleri M, McKinzie, et al. Gender-related differences in slowing colonic by a 5-HT3 antagonist in subjects with diarrhea-predominant IBS. Am J Gastroenterol 2001; 96: 2671 – 6.en_US
dc.identifier.citedreference16.  Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Adverse event reporting system (AERS). Available at: http://www.Fda/gov/cder/aers/default.htm.en_US
dc.identifier.citedreference17.  GlaxoSmithKline. Lotronex (alosetron hydrochloride tablets). Briefing document for the Joint Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Sub-Committee. April 23, 2002. Rockville, MD: U.S. Food and Drug Administration.en_US
dc.identifier.citedreference18.  GlaxoSmithKline. Lotronex (alosetron hydrochloride tablets). Briefing document for the Joint Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Sub-Committee. May 5, 2004. Rockville, MD: U.S. Food and Drug Administration.en_US
dc.identifier.citedreferenceCamilleri M, Chey WY, Mayer EA, et al. A randomized controlled trial of the serotonin type 3 antagonist alosetron in women with diarrhea-predominant IBS. Arch Intern Med 2001; 161: 1733 – 40.en_US
dc.identifier.citedreferenceWolfe S, Chey W, Washington MK, et al. Tolerability of the 5HT3 receptor antagonist alosetron following long-term administration in female and male IBS patients. Am J Gastroenterol 2001; 96: 803 – 11.en_US
dc.identifier.citedreferenceTalley N, van Zanten S, Dukes G, et al. A dose ranging, randomized, placebo-controlled, clinical trial of alosetron in subjects with functional dyspepsia. Aliment Pharmacol Ther 2001; 15 ( 4 ): 525 – 37.en_US
dc.identifier.citedreferenceCremonini F, Delgardo-Aros S, Camilleri M. Efficacy of alosetron in IBS: A meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003: 15: 79 – 86.en_US
dc.identifier.citedreferenceHiggins PDR, Davis KJ, Laine L. Systematic review: The epidemiology of ischemic colitis. Aliment Pharmacol Ther 2004; 19: 729 – 38.en_US
dc.identifier.citedreferenceWalker AM, Bohn RL, Cali C, et al. Risk factors for colon ischemia. Am J Gastroenterol 2004; 99: 1333 – 7.en_US
dc.identifier.citedreferenceSingh G, Mithal A, Triadafilopoulos G. Patients with irritable bowel syndrome have a high-risk of developing ischemic colitis [abstract]. Gastroenterology 2004; 126: A349.en_US
dc.identifier.citedreferenceCole JA, Cook SF, Sands BE, et al. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004; 99: 486 – 91.en_US
dc.identifier.citedreferenceBrinker A, Senior J, Beitz J. Misdiagnosis of ischemic colitis as irritable bowel syndrome [abstract]. Clin Pharmacol Ther 2003; 73: P33.en_US
dc.identifier.citedreference28.  American Gastroenterological Association. The burden of gastrointestinal diseases. Bethesda, MD: AGA Press, 2001: 27 – 9.en_US
dc.identifier.citedreferenceCoates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657 – 64.en_US
dc.identifier.citedreferenceBeck IT. Possible mechanisms for ischemic colitis during alosetron therapy. [ letter ] Gastroenterology 2001; 121: 231 – 2.en_US
dc.identifier.citedreferenceVanner S. Myenteric neurons activate submucosal vasodilator neurons in guinea pig ileum. Am J PhysiolGastrointest Liver Physiol 2000; 279: G380 – 7.en_US
dc.identifier.citedreferenceMiller DP, Alfredson T, Cook S, et al. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol 98: 1117 – 22.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2006.00459.x.pdf
Size:
246.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.